{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}],"title":"Participants with at least 1 positive titer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Neutralizing antibody detected"}],"denoms":[{"counts":[{"groupId":"OG000","value":"528"}],"units":"Participants"}],"description":"A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.","groups":[{"description":"Necitumumab + Gemcitabine + Cisplatin\n\nNecitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.\n\nContinues until progressive disease, toxicity, noncompliance, or withdrawal.\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG000","title":"Necitumumab + Gemcitabine + Cisplatin"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received who received at least 1 dose of drug and had evaluable data for antibodies.","reportingStatus":"POSTED","timeFrame":"Baseline through 31 Months","title":"Number of Participants With a Serum Anti-Necitumumab Antibody Assessment","type":"SECONDARY","unitOfMeasure":"participants"}